Test drug to slow kidney damage in type 2 diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This Phase 2 study compares tofogliflozin to metformin to see how well they reduce urine albumin levels (a marker of kidney stress) in people with diabetic kidney disease. You might benefit if your type 2 diabetes is affecting your kidneys despite standard blood-pressure medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes
- You are 20 years old or older
- Your recent A1c (average blood sugar) is between 6.5% and 9.0%
- You have diabetic kidney disease shown by your urine albumin-to-creatinine ratio (UACR) being 30 to under 2000
- Your kidneys are working enough for the study (eGFR 30 or higher)
- You have been on a kidney-protecting blood pressure medicine called a RAS inhibitor (ACE/ARB/ARNI or similar) for at least 4 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medicine called ganagliflozin can slow down kidney damage in people with type 2 diabetes and chronic kidney disease. If you qualify, you may be able to take part in this study to see if it helps protect your kidneys.
This study tests whether a daily medication can slow down kidney damage in people with type 1 diabetes who already have some kidney problems. It may help protect your kidneys from getting worse.
This study tests how a drug called canagliflozin (an SGLT2 inhibitor) affects kidney function in people with type 2 diabetes. It involves two kidney biopsies to see how the drug works inside your kidneys, aiming to better protect kidney health.
This Phase 3 trial tests whether starting a diabetes medicine called dapagliflozin can better slow kidney damage than starting metformin in adults with type 2 diabetes. It may help preserve kidney function over time and reduce future kidney decline.
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
This study looks at whether a urine test can help doctors choose the right medicines earlier to prevent kidney and heart problems in people with type 2 diabetes. You may join if you have type 2 diabetes but no severe heart failure.
Hear when a new Metformin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.